|$53M||14 Jul 2021||Los Angeles, California, United States|
|$32M||06 Apr 2021||New York, New York, United States|
ATAI Life Sciences
|$157M||03 Mar 2021||Bavaria|
|$60M||11 Feb 2021||New York, United States|
Personal Genome Diagnostics
|$103M||10 Feb 2021||Baltimore, Maryland, United States|
|$60M||09 Feb 2021||New York, New York, United States|
|$64M||27 Jan 2021||Santa Clarita, California, United States|
|$125M||14 Jan 2021||New York, New York, United States|
|$30M||11 Jan 2021||Maryland, United States|
– DNA Script announced it has raised $165m in a Series C financing round.
– The round was led by Coatue Management and Catalio Capital Management, whose representatives have joined as Board observers.
– The new funds will be used to accelerate expansion and commercialization of the company’s revolutionary SYNTAX Platform and broaden the portfolio of products powered by EDS.
– The SYNTAX Platform provides in-house DNA printing – without using toxic organic chemicals or extended delivery wait times from third-party DNA service providers – for labs of all sizes.
– Entos, Inc. (“Entos” or “the Company”), the creator of a cutting-edge platform combining AI-driven technology and automated synthetic development to design small-molecule therapeutics, announced the closing of a $53 million Series A.
– The financing round was led by Coatue, a leading technology investment firm, and Catalio Capital Management, a leading biomedical technology investment firm, with participation from OrbiMed and Sequoia Capital as well as existing investors Nexus Ventures and Freeflow.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.